Product Description
CoviDx™ SARS-CoV-2 Rapid Antigen Test is a rapid immunoassay for the qualitative detection of the nucleocapsid protein in nasal swabs (NS), oropharyngeal swabs (OP), and nasopharyngeal swabs (NP) from patients suspected of a Coronavirus-19 (COVID-19) infection.

CoviDx is intended for use by trained laboratory personnel and healthcare professionals.

Results in 15 minutes.

  • CoviDx allows for optimal disease management and immediate patient isolation
  • Detects UK, South African, and Danish COVID-19 variant strains1
  • Pre-filled extraction vials and individually wrapped swabs enable multiple independent workstations for increased test distribution
  • Facilitates professionally administered testing at the point of need, such as workplace testing and airport screening
  • Room temperature storage
  • 25 test kit
Background Information
SARS-CoV-2 is a new coronavirus that was identified in December 2019 and can cause mild to severe illness—COVID-19. Due to its highly contagious nature and global health crises, SARS-CoV-2 was designated as a pandemic by the World Health Organization (WHO) in March 2020. The ability to rapidly identify COVID-19 patients to enable effective cohorting and prevent the spread of infection is a critical component of combatting the pandemic.
Rapid antigen tests are an important tool in the overall response against COVID-19 and to benefit public health. The main advantages of antigen testing are the speed and simplicity of the test, which can provide results in minutes. Through rapid detection of SARS-CoV-2, CoviDx is able to optimise patient isolation decisions and enable accurate cohorting.
Intended Use Statement
CoviDx SARS-CoV-2 Rapid Antigen Test is a rapid immunoassay for the qualitative detection of the nucleocapsid protein in nasal swabs (NS), oropharyngeal swabs (OP), and nasopharyngeal swabs (NP) from patients suspected of a Coronavirus-19 (COVID-19) infection.

CoviDx SARS-CoV-2 Rapid Antigen Test aids in the clinical diagnosis of patients suspected of COVID-19. The test is intended for professional use and should be used in conjunction with other clinical evidence.

Negative results should be considered presumptive and do not preclude infection. Negative results should not be used as the sole basis for diagnosis, treatment, or other clinical and patient management decisions and should be confirmed with a molecular test for SARS-CoV-2.

CoviDx SARS-CoV-2 Rapid Antigen Test does not differentiate between SARS-CoV and SARS-CoV-2.


  • CoviDx SARS-CoV-2 Rapid Antigen Test is CE marked and is in process of regulatory registration as required in various markets.

Contact us to order or learn more about the CoviDx SARS-CoV-2 Rapid Antigen Test.